Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

Fig. 7

Schematic representation of the putative synergy mechanism between irinotecan, BKM 120 and MEK162. (a) Irinotecan treatment induce an increase of phosphorylation of INSR, which in turn activate PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways and stimulate tumor cell survival and growth. (b) The combination of irinotecan, BKM120 and MEK162 abrogates the effect of IR activation and favors tumor cell proliferation arrest and apoptosis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us